Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Banning Group conducts predominantly clinical research in interventional cardiology, with a focus on improving outcomes for patients with cardiovascular disease. Our work spans early-phase and multicentre clinical trials, advanced coronary physiology, and intravascular imaging. We also evaluate novel devices and therapies to translate innovation rapidly into clinical practice.

Image of the heart

The Banning Group is led by Professor Adrian Banning (www.thecardiologist.co.uk), one of the UK’s leading interventional cardiologists, internationally recognised for excellence in both clinical practice and cardiovascular research. Professor Banning has been a senior interventional cardiologist in Oxford since 1995 and is a former President of the British Cardiac Intervention Society.

The overarching aim of the Banning Group is to improve the care and outcomes of patients with cardiovascular disease. Our research spans the full translational spectrum, from studies exploring the underlying mechanisms of cardiovascular disease to the evaluation of novel diagnostic and therapeutic technologies in interventional cardiology.

Our current key areas of research interest include:

  • Early-stage clinical trials in cardiology
  • Large-scale, multi-centre clinical trials
  • Medical device development and evaluation
  • Invasive assessment of coronary physiology
  • Intravascular imaging
  • Myocardial infarction, with a particular focus on ST-segment elevation myocardial infarction (STEMI)
  • Renal denervation for the optimisation of hypertension management

Recent work includes the first randomised controlled trial evaluating stent‑retriever thrombectomy in ST‑segment elevation myocardial infarction with a large thrombus burden (the RETRIEVE‑AMI trial). Ongoing research focuses on the development of machine learning based approaches to enhance the effectiveness of renal denervation procedures, as well as developing automated thrombus analysis using intravascular imaging during myocardial infarction.

Our team

Selected publications

LAb alumni

Jason Leo Walsh (UK)

Alessandro Maino (Italy)

Steffano Bonetti (Italy)

Alice Boroni (Italy)

Maria Emfietzoglou (Greece)

Claudio Montalto (Italy)

Federico Marin (Italy) 

Roberto Scarsini (Italy)

Dimitris Terentes-Printzios (Greece)

Gregor Fahrni (Switzerland)

Mathias Wolfrum (Switzerland)

Giovanni Luigi De Maria (Italy)

George Kassimis (Greece)

Niket Patel (UK)

Florim Cuculi (Switzerland)

Chris Lim (Australia)

Luca Testa (Italy)

Barton Jennings (Australia)

Adrian Cheng (UK)

Bill Van Gall (Australia)

Ranjit Arnold (UK)

Vishali Asher (UK)

Dermot Nicholson (South Africa)

Italo Porto (Italy)

Giampaulo Niccoli (Italy)